Effect of salvia miltiorrhiza pretreatment on the CCK and VIP expression in hepatic ischemia-reperfusion-induced digestive tract congestion

Frontiers of Medicine in China

Volumn 4, Issue 3, 2010, Pages 317-322

  Zhang, Zhi Yong ^a   Chen, Xiao Ping ^a   Lu, Qi Ping ^b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b WUHAN GENERAL HOSPITAL OF GUANGZHOU COMMAND   (China)

Author keywords

cholecystokinin; digestive tract congestion; hepatic ischemia reperfusion; salvia miltiorrhiza; vasoactive intestinal peptide

Indexed keywords

CHOLECYSTOKININ; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANIMAL; ARTICLE; BIOSYNTHESIS; DRUG EFFECT; GASTROINTESTINAL MOTILITY; INTESTINE MUCOSA; JEJUNUM; LIVER; LIVER DISEASE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PHYTOTHERAPY; RAT; REPERFUSION INJURY; SALVIA MILTIORRHIZA; SPRAGUE DAWLEY RAT;

ANIMALS; CHOLECYSTOKININ; GASTROINTESTINAL MOTILITY; INTESTINAL MUCOSA; JEJUNUM; LIVER; LIVER DISEASES; PHYTOTHERAPY; RATS; RATS, SPRAGUE-DAWLEY; REPERFUSION INJURY; SALVIA MILTIORRHIZA; VASOACTIVE INTESTINAL PEPTIDE;

EID: 77956647245     PISSN: 16737342     EISSN: 16737458     Source Type: Journal    
DOI: 10.1007/s11684-010-0035-4     Document Type: Article

References (26)

1. Liu Y P, Liu J S. The progress of mechanism of liver ischemia-reperfusion. Linchuang Yanjiu Zazhi, 2008, 25(10): 1904-1907 (in Chinese).
2. Devey L, Ferenbach D, Mohr E, Sangster K, Bellamy C O, Hughes J, Wigmore S J. Tissue-resident macrophages protect the liver from ischemia reperfusion injury via a heme oxygenase-1-dependent mechanism. Mol Ther, 2009, 17(1): 65-72.
3. Tsung A, Klune J R, Zhang X, Jeyabalan G, Cao Z, Peng X, Stolz D B, Geller D A, Rosengart M R, Billiar T R. HMGB1 release induced by liver ischemia involves Toll-like receptor 4 dependent reactive oxygen species production and calcium-mediated signaling. J Exp Med, 2007, 204(12): 2913-2923.
4. Zhong Z, Ramshesh V K, Rehman H, Currin R T, Sridharan V, Theruvath T P, Kim I, Wright G L, Lemasters J J. Activation of the oxygen-sensing signal cascade prevents mitochondrial injury after mouse liver ischemia-reperfusion. Am J Physiol Gastrointest Liver Physiol, 2008, 295(4): G823-G832.
5. Vardanian A J, Busuttil R W, Kupiec-Weglinski J W. Molecular mediators of liver ischemia and reperfusion injury: a brief review. Mol Med, 2008, 14(5-6): 337-345.
6. Fu R, Shen H. A technical study on C-mean clustering segmentation for color immunohistochemical image based on matlab. Zhongguo Tishixue Yu Tuxiang Fenxi, 2007, 12(1): 6-10(in Chinese).
7. Zhang N, Tao K, Huang T. Effects of meloxicam on vascular endothelial growth factor and angiopoietin-2 expression in colon carcinoma cell line HT-29. J Huazhong Univ Sci Technolog Med Sci, 2007, 27(4): 399-402.
8. Wan C, Wang H, Cheng R, Gou S, Liu T. Effect of target-directed regulation of uncoupling protein-2 gene expression on ischemia-reperfusion injury of hepatocytes. J Huazhong Univ Sci Technol Med Sci, 2008, 28(5): 558-563.
9. Chen J, Wang G. Role of nuclear factor kappaB in intestine injury induced by hepatic ischemia reperfusion. J Huazhong Univ Sci Technol Med Sci, 2004, 24(3): 284-285, 291.
10. Zhang J, Wu H, Wang L, Zhang J, Wang H, Zheng Q. TLR2 mRNA upregulation in ischemic lobes in mouse partial hepatic ischemia/reperfusion injury model. J Huazhong Univ Sci Technol Med Sci, 2004, 24(2): 144-146.
11. 2+ channel currents of hepatocytes after hepatic ischemia/reperfusion injury in rats. J Huazhong Univ Sci Technol Med Sci, 2005, 25(1): 39-41.
12. Cai H, Guang Y, Liu L. The protective effects of in vitro cultivated calculus bovis on the cerebral and myocardial cells in hypoxic mice. J Huazhong Univ Sci Technol Med Sci, 2007, 27(6): 635-638.
13. D'Alessio D. Intestinal hormones and regulation of satiety: the case for CCK, GLP-1, PYY, and Apo A-IV. JPEN, 2008, 32(5): 567-568.
14. Raybould H E. Mechanisms of CCK signaling from gut to brain. Curr Opin Pharmacol, 2007, 7(6): 570-574.
15. Berna M J, Jensen R T. Role of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases. Curr Top Med Chem, 2007, 7(12): 1211-1231.
16. Miller L J, Gao F. Structural basis of cholecystokinin receptor binding and regulation. Pharmacol Ther, 2008, 119(1): 83-95.
17. Bai J, Lü Y, Bai Q. Construction of porcine CCK pDNA and its expression in COS-7 cells. J Huazhong Univ Sci Technol Med Sci, 2007, 27(3): 278-280.
18. Tang M, Ni H, Xu L. Changes in the mRNA concentration of preprocholecystokinin in rat cerebral cortex and hippocampus after gastric distension. Acta Physiologica Sinica, 1999, 51(5): 488-494.
19. Onoue S, Misaka S, Yamada S. Structure-activity relationship of vasoactive intestinal peptide (VIP): potent agonists and potential clinical applications. Naunyn Schmiedebergs Arch Pharmacol, 2008, 377(4-6): 579-590.
20. Masmoudi-Kouki O, Gandolfo P, Castel H, Leprince J, Fournier A, Dejda A, Vaudry H, Tonon M C. Role of PACAP and VIP in astroglial functions. Peptides, 2007, 28(9): 1753-1760.
21. Watanabe S. Vasoactive intestinal polypeptide (VIP). Nippon Rinsho, 2005, 63(Suppl 8): 502-504.
22. Reich A, Szepietowski J C. Vasoactive peptides in the pathogenesis of psoriasis. G Ital Dermatol Venereol, 2008, 143(5): 289-298.
23. Yoshiyama M, de Groat W C. The role of vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide in the neural pathways controlling the lower urinary tract. J Mol Neurosci, 2008, 36(1-3): 227-240.
24. Langer I, Robberecht P. Molecular mechanisms involved in vasoactive intestinal peptide receptor activation and regulation: current knowledge, similarities to and differences from the A family of G-protein-coupled receptors. Biochem Soc Trans, 2007, 35(Pt 4): 724-728.
25. Gong S, Ding J, Chang Q. The expression of VIP and SP in the cochlea of spontaneously hypertensive rats and its implication. J Huazhong Univ Sci Technol Med Sci, 2004, 24(4): 396-399.
26. Muller J M, Philippe M, Chevrier L, Héraud C, Alleaume C, Chadéneau C. The VIP-receptor system in neuroblastoma cells. Regul Pept, 2006, 137(1-2): 34-41.